Ao Qiong Li

This inventor holds 10 USPTO granted patents and 9 published patent applications and 1 EPO patent. Top assignees: Chia Tai Tianqing Pharmaceutical Group Co., Ltd., International Business Machines Corporation, Minghui Pharmaceutical (Hangzhou) Limited. Active years: 2018-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ao Qiong Li. Retrieved from https://idiyas.com/inventor/ao-qiong-li

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 10 (Patent Applications = 9)

% Patents Active = 90.0

EPO Patents = 1 (Patent Applications = 10)

Average Co-Inventor Count = 5.8

ph-index = 1

Forward Citations = 2(Granted Patents)

Location History:

Beijing, CN (2018)
Shanghai, CN (2020 - 2023)

Company Filing History:

2 out of 121

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

patents

2 out of 166,351

International Business Machines Corporation

patents

2 out of 2

Minghui Pharmaceutical (Hangzhou) Limited

patents

4. 2 out of 2

Minghui Pharmaceutical (Shanghai) Limited

patents

5. 1 out of 1

Js Innomed Holdings Ltd.

patent

6. 1 out of 3

Js Innopharm (Shanghai) Ltd.

8. 1 out of 834,513

Other

patents

where one patent can have more than one assignee

Years Active: 2018-2026

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12698292 - Toxin molecule suitable for antibody-drug conjugate (2026-08-04),

2. 12682675 - Extensible architecture with multimodal feature fusion for document classification (2026-07-14),

3. 12384786 - Cyclic molecules as Bruton's tyrosine kinase inhibitor (2025-08-12),

4. 12133841 - Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof (2024-11-05),

5. 11548868 - Heterocyclic compounds, compositions comprising heterocyclic compound, and methods of use thereof (2023-01-10),

6. 11524958 - Tricyclic compound as CRTH2 inhibitor (2022-12-13),

7. 11449465 - Fixed chunk size deduplication with variable-size chunking (2022-09-20),

8. 11087129 - Interactive virtual simulation system (2021-08-10),

9. 10800765 - Indole derivative used as CRTH2 inhibitor (2020-10-13),

10. 10033526 - One INS network-based anti-fault attack method of random infection (2018-07-24),

Title: Innovations and Contributions of Inventor Ao Qiong Li

Introduction

Ao Qiong Li is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of kinase inhibitors. With a total of 8 patents to his name, his work has the potential to impact the treatment of various diseases, including cancers.

Latest Patents

Among his latest patents, one notable invention is related to cyclic molecules as Bruton's tyrosine kinase inhibitors. This invention focuses on a novel molecule with protein tyrosine kinase inhibitory activity, detailing the synthesis and usage of the compound. Another significant patent involves heterocyclic compounds as kinase inhibitors, which includes therapeutic uses of these compounds. This patent also describes a pharmaceutical composition that comprises a compound of Formula (I) and a pharmaceutically acceptable carrier.

Career Highlights

Throughout his career, Ao Qiong Li has worked with reputable organizations, including IBM and Chia Tai Tianqing Pharmaceutical Group Co., Ltd. His experience in these companies has contributed to his expertise in the field of drug development and innovation.

Collaborations

He has collaborated with notable coworkers such as Yuanshan Yao and Yicheng Feng, further enhancing his research and development efforts.

Conclusion

Ao Qiong Li's innovative work in the field of kinase inhibitors showcases his dedication to advancing pharmaceutical science. His contributions have the potential to lead to significant advancements in the treatment of various diseases.

Profile summary based on public USPTO records.